The following perpetrator compounds were selected:

- **Atazanavir** (UGT1A1 inhibitor), PBPK model v1.0 description and evaluation in
  https://github.com/Open-Systems-Pharmacology/Atazanavir-Model/releases/tag/v1.0 

- **Mefenamic acid** (UGT1A9 inhibitor), PBPK model v1.0 description and evaluation in
 https://github.com/Open-Systems-Pharmacology/Mefenamic-acid-Model/releases/tag/v1.0 

  

The following sensitive substrates as victim drugs were selected:

- **Raltegravir** (UGT1A1 substrate), PBPK model v1.0 description and evaluation in
  https://github.com/Open-Systems-Pharmacology/Raltegravir-Model/releases/tag/v1.0 
  
- **Dapagliflozin** (UGT1A9 substrate), PBPK model v1.0 description and evaluation in
  https://github.com/Open-Systems-Pharmacology/Dapagliflozin-Model/releases/tag/v1.0 
  
  â€‹	

Corresponding DDI modelling files can be found in:

- **Atazanavir-Raltegravir-DDI** (v1.0):
  https://github.com/Open-Systems-Pharmacology/Atazanavir-Raltegravir-DDI/releases/tag/v1.0
- **Mefenamic acid-Dapagliflozin-DDI** (v1.0):
  https://github.com/Open-Systems-Pharmacology/Mefenamic_acid-Dapagliflozin-DDI/releases/tag/v1.0



The following sections give an overview of the clinical studies being of this qualification report.